Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2021-02-22 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Voluntary withdrawal Imfinzi US bladder indication
Regulatory Filings Classification · 100% confidence The document is clearly identified as an 'RNS Number' release from AstraZeneca PLC, dated February 22, 2021. It announces a specific corporate action: the 'Voluntary withdrawal of Imfinzi indication in advanced bladder cancer in the US' in consultation with the FDA. This type of announcement, which conveys material, non-financial news (like regulatory interactions or product updates) via the London Stock Exchange's news service (RNS), fits best under the general 'Regulatory Filings' category, as it is not a specific financial report (like 10-K, ER, or IR), a management change (MANG), or a shareholder vote result (DVA). Since it is a direct regulatory/news service announcement and doesn't fit the specific definitions for financial reports or corporate governance documents, RNS is the most appropriate fallback.
2021-02-22 English
F-4
Merger & Acquisition Classification · 100% confidence The document is a Form F-4 registration statement filed with the U.S. Securities and Exchange Commission, which is used for securities registration in connection with mergers and acquisitions. It includes a proxy statement and prospectus related to the proposed merger of Alexion Pharmaceuticals, Inc. by AstraZeneca PLC. The text discusses the merger agreement, exchange ratio, voting proposals for stockholders, and other merger-related details. This type of filing is specifically related to merger and acquisition activity, not a general annual report, earnings release, or other categories. Therefore, the appropriate classification is Merger & Acquisition (MA). The document length and content confirm it is the actual filing, not just an announcement or proxy solicitation alone.
2021-02-19 English
LYNPARZA: IDMC RECOMMEND EARLY ANALYSIS OF OLYMPIA
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about the Independent Data Monitoring Committee (IDMC) recommendation for early analysis of the OlympiA Phase III trial of Lynparza. The content focuses on clinical trial updates, drug development, and company background rather than financial results or management changes. Form 6-K filings are typically used by foreign private issuers to report material information that is not required in annual or quarterly reports. This document is not an annual report, earnings release, management report, or any other specific financial or governance report. It is a regulatory filing providing material information to the SEC and investors. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and detailed content confirm it is a substantive filing, not a brief announcement or certification.
2021-02-17 English
Lynparza: IDMC recommend early analysis of OlympiA
Regulatory Filings Classification · 98% confidence The document is identified by the RNS Number (3943P) and the date stamp (17 February 2021 07:00 GMT), indicating it is a regulatory announcement disseminated via the Regulatory News Service (RNS). The content describes a significant clinical trial update (OlympiA trial for Lynparza) where the IDMC recommended early primary analysis because the superiority boundary for iDFS was crossed. This is a material event announcement concerning clinical data, not a full financial report (like 10-K or IR) or a general proxy/dividend notice. Since it is a specific regulatory announcement that doesn't fit perfectly into categories like ER, DIV, or CAP, and it is clearly a formal regulatory news release, the most appropriate classification is the general regulatory filing category, RNS, as it is the primary mechanism for disseminating such news.
2021-02-17 English
IRANNOTICE
Regulatory Filings Classification · 95% confidence The document is a notice filed with the U.S. Securities and Exchange Commission referencing disclosures made in AstraZeneca's Annual Report on Form 20-F for the year ended December 31, 2020. It specifically states that the disclosure is pursuant to the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act. The document itself is a short notice indicating that the disclosure is contained within the Annual Report, not the report itself. The document length is only 1889 characters, which is quite short and consistent with a regulatory filing or notice rather than a full report. It is primarily an attestation or certification of disclosure rather than containing substantive financial data or the full report. Therefore, according to the rules, this should be classified as a Regulatory Filing (RNS) rather than the Annual Report (10-K or 20-F).
2021-02-16 English
FILING OF FORM 20-F WITH SEC
Report Publication Announcement Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, announcing the filing of its 2020 Annual Report on Form 20-F with the SEC. The text states that the Annual Report on Form 20-F has been filed and is available on the SEC website. The document itself is short (3100 characters) and primarily serves as an announcement of the filing rather than containing the full annual report or detailed financial data. According to the 'MENU VS MEAL' rule, such a short announcement that states a report has been filed and is available elsewhere should be classified as a Report Publication Announcement (RPA), not as the Annual Report (10-K or 20-F) itself. Therefore, the correct classification is RPA with high confidence.
2021-02-16 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.